Source - RNS
RNS Number : 2491J
Redx Pharma plc
08 September 2016






("Redx" or "the Company")


Board and Senior Management Changes


Redx, the drug development company, announces that Phil Tottey, Chief Financial Officer, will be stepping down from the Board and leaving the Company on 30 September 2016 to pursue new opportunities. Andrew Booth, who is currently Financial Controller, will act as Interim Finance Director pending a permanent appointment.


At the same time, the Board is pleased to welcome Karl Hård to the Executive Management Team as Head of Investor Relations and Corporate Communications. Karl has spent almost 20 years at AstraZeneca PLC. Over the last nine years, he held senior roles within Investor Relations, latterly as Vice President.  Before that, he worked as Global Programme Director, establishing new external collaborations, and as Director in Biological Chemistry, leading research into novel pharmacological targets. His scientific experience covers oncology, immunology and infection.   


Karl was Assistant Professor in Chemistry at Leiden University, The Netherlands, and holds a PhD in Chemistry from Utrecht University, and an MSc in Biochemistry from Helsinki University, Finland.


Neil Murray, Chief Executive of Redx, commented:

"On behalf of the Board, I would like to thank Phil for his significant contribution to Redx and particularly for his work during the Company's IPO. We wish him well in his future endeavours.


I am very pleased to welcome Karl Hård to Redx as Head of Investor Relations. His long career at AstraZeneca, which encompassed both scientific research and investor relations, means that he will be a valuable addition to the management team.  We look forward to working with him as we drive forward Redx's continuing development."



For further information, please contact:


Redx Pharma Plc

T: 0151 706 4747

Neil Murray, Chief Executive

Company website: 


Cantor Fitzgerald Europe (Nomad & Broker)

T: 020 7894 7000

Phil Davies / Michael Reynolds


KTZ Communications

T: 020 3178 6378

Katie Tzouliadis/ Viktoria Langley/ Emma Pearson




About Redx Pharma Plc


Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Seven pre-clinical proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers.


This information is provided by RNS
The company news service from the London Stock Exchange